Literature DB >> 10228067

The effects of aerosolized dextran in a mouse model of Pseudomonas aeruginosa pulmonary infection.

R Bryan1, M Feldman, S C Jawetz, S Rajan, E DiMango, H B Tang, L Scheffler, D P Speert, A Prince.   

Abstract

Airway infections initiated by the interaction of bacterial adhesins with carbohydrate receptors can be potentially prevented by nontoxic carbohydrate inhibitors. Intranasal inoculation of neonatal mice with Pseudomonas aeruginosa PAO1 caused pneumonia in 55% of control mice but in only 13% of mice inoculated 2 h after dextran inhalation (P<.001) and in 28% inoculated 4 h after dextran inhalation (P=.02). PAO1 adherence to epithelial cells was inhibited by 50% in the presence of dextran. Dextran was well distributed throughout the airways and stimulated tumor necrosis factor-alpha production in murine lungs but not interleukin-8 production by human epithelial cell lines. Phagocytosis of PAO1 was not affected by dextran nor was killing by human neutrophils diminished. Administration of dextran by aerosol may prevent murine pneumonia by impeding bacterial access to epithelial receptors and by stimulation of the immune functions of the epithelium.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10228067     DOI: 10.1086/314755

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  9 in total

Review 1.  New therapeutic approaches for cystic fibrosis lung disease.

Authors:  Jane C Davies
Journal:  J R Soc Med       Date:  2002       Impact factor: 5.344

2.  CXC chemokine receptor CXCR2 is essential for protective innate host response in murine Pseudomonas aeruginosa pneumonia.

Authors:  W C Tsai; R M Strieter; B Mehrad; M W Newstead; X Zeng; T J Standiford
Journal:  Infect Immun       Date:  2000-07       Impact factor: 3.441

Review 3.  Receptor mimicry as novel therapeutic treatment for biothreat agents.

Authors:  Richard J Thomas
Journal:  Bioeng Bugs       Date:  2010 Jan-Feb

4.  Role of LecA and LecB lectins in Pseudomonas aeruginosa-induced lung injury and effect of carbohydrate ligands.

Authors:  Chanez Chemani; Anne Imberty; Sophie de Bentzmann; Maud Pierre; Michaela Wimmerová; Benoît P Guery; Karine Faure
Journal:  Infect Immun       Date:  2009-02-23       Impact factor: 3.441

5.  Nebulized heparin is associated with fewer days of mechanical ventilation in critically ill patients: a randomized controlled trial.

Authors:  Barry Dixon; Marcus J Schultz; Roger Smith; James B Fink; John D Santamaria; Duncan J Campbell
Journal:  Crit Care       Date:  2010-10-11       Impact factor: 9.097

Review 6.  Targeting inhaled therapy beyond the lungs.

Authors:  Ninell P Mortensen; Anthony J Hickey
Journal:  Respiration       Date:  2014       Impact factor: 3.966

7.  A quadruple knockout of lasIR and rhlIR of Pseudomonas aeruginosa PAO1 that retains wild-type twitching motility has equivalent infectivity and persistence to PAO1 in a mouse model of lung infection.

Authors:  James J Lazenby; Phoebe E Griffin; Jennelle Kyd; Cynthia B Whitchurch; Margaret A Cooley
Journal:  PLoS One       Date:  2013-04-10       Impact factor: 3.240

8.  A phase 1 trial of nebulised heparin in acute lung injury.

Authors:  Barry Dixon; John D Santamaria; Duncan J Campbell
Journal:  Crit Care       Date:  2008-05-06       Impact factor: 9.097

Review 9.  Nebulised heparin as a treatment for COVID-19: scientific rationale and a call for randomised evidence.

Authors:  Frank M P van Haren; Clive Page; John G Laffey; Antonio Artigas; Marta Camprubi-Rimblas; Quentin Nunes; Roger Smith; Janis Shute; Mary Carroll; Julia Tree; Miles Carroll; Dave Singh; Tom Wilkinson; Barry Dixon
Journal:  Crit Care       Date:  2020-07-22       Impact factor: 9.097

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.